Young K. Chae
Experienced in Polymorphous Low Grade Adenocarcinoma

Dr. Young K. Chae

Hematology | Oncology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
Offers Telehealth
23 Years of Experience
Experienced in Polymorphous Low Grade Adenocarcinoma
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Young Chae is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chae has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Seoul National University College Of Medicine, 2002
Residency
Albert Einstein Healthcare Network
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Medical Oncology (Certified)
Fellowships
University of Texas Health Science Center at Houston/M D Anderson Cancer Center
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

233 E Superior St 1st Fl, Olson Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Chae has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Enrollment Status: Terminated
Publish Date: February 03, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60mg/m2 Administered During a 60 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80mg/m2 Administered During a 80 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors.
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60mg/m2 Administered During a 60 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80mg/m2 Administered During a 80 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Enrollment Status: Completed
Publish Date: June 26, 2023
Intervention Type: Drug
Study Drugs: RMC-4630, Cobimetinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 25, 2022
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors
Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors
Enrollment Status: Unknown
Publish Date: October 14, 2020
Intervention Type: Drug, Biological, Other
Study Drugs: Metformin Hydrochloride, Nivolumab
Study Phase: Phase 2
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
Enrollment Status: Unknown
Publish Date: February 01, 2019
Intervention Type: Drug
Study Drugs: COTI2, Cisplatin
Study Phase: Phase 1
View 20 Less Clinical Trials

162 Total Publications

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.
Journal: Journal for immunotherapy of cancer
Published: June 06, 2025
Similar Doctors
Jochen H. Lorch
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Jochen H. Lorch
Hematology | Oncology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Jochen H. Lorch
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
31+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jochen Lorch is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lorch has been practicing medicine for over 31 years and is rated as an Elite provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, Adenoid Cystic Carcinoma, and Thyroidectomy.

Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Nicholas P. Campbell
Oncology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Nicholas P. Campbell
Oncology

Endeavor Health Medical Group

5140 N California Ave, 
Chicago, IL 
 (7.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicholas Campbell is an Oncologist in Chicago, Illinois. Dr. Campbell is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Campbell is currently accepting new patients.

Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Bruce E. Brockstein
Oncology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Bruce E. Brockstein
Oncology

Endeavor Health Medical Group

2650 Ridge Ave, 
Evanston, IL 
 (12.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Brockstein is an Oncologist in Evanston, Illinois. Dr. Brockstein is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma. Dr. Brockstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chae's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 68 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile